GlassScriptPhysician profile
Monica Mccawley
NPI 1780266163
$10,060.73
in general payments reported to CMS, 2019-2025
33 companies · $2,435 in 2025
The $2,435 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,335 · 2022: $3,066 · 2023: $1,319 · 2024: $1,905 · 2025: $2,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,560 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,560.10 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,498.37 | 2022-2025 | |
| Viiv Healthcare Company | $1,709.35 | 2021-2024 | Dovato, Apretude, Cabenuva |
| Janssen Biotech, INC. | $1,551.13 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,123.59 | 2021-2025 | Entyvio |
| Pfizer INC. | $507.41 | 2022-2025 | |
| Qol Medical, LLC | $397.69 | 2021-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $377.75 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $320.27 | 2021-2025 | Omvoh |
| Bayer Healthcare Pharmaceuticals INC. | $146.35 | 2021-2022 | |
| Celltrion USA INC. | $141.91 | 2024-2025 | Zymfentra, Vegzelma |
| Merck Sharp & Dohme LLC | $114.26 | 2021-2022 | |
| Janssen Products, LP | $99.95 | 2021 | |
| Janssen Pharmaceuticals, INC | $99.20 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $96.94 | 2022-2023 | |
| Celgene Corporation | $94.23 | 2022-2024 | Zeposia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $88.28 | 2023-2025 | Sutab, Suflave |
| Kestra Medical Technology Services, INC. | $84.84 | 2022-2023 | Assure Wcd |
| Amgen INC. | $67.99 | 2021-2022 | |
| Genzyme Corporation | $62.80 | 2024-2025 | |
| Theratechnologies INC. | $53.76 | 2021-2022 | |
| Novo Nordisk INC | $53.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.83 | 2022-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $46.37 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $44.49 | 2021 | |
| Emd Serono, INC. | $44.15 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.18 | 2022 | |
| Fresenius Kabi USA, LLC | $32.10 | 2023 | |
| Alnylam Pharmaceuticals INC. | $25.59 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.39 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.02 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.57 | 2024 | Voquezna |
| Pharmacosmos Therapeutics INC. | $17.43 | 2025 | Monoferric |
| Acerus Pharmaceuticals Corporation | $15.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Mccawley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.